Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
about
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values.Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.Utilizing next-generation sequencing in the management of multiple myeloma.Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.Mutational landscape reflects the biological continuum of plasma cell dyscrasias.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse.Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.Loss of FAM46C Promotes Cell Survival in Myeloma.A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
P2860
Q26740359-6412D946-077F-488B-94A2-BF02CC5A03C2Q36306807-3F610469-999B-4DE5-BC01-81255CBB161DQ37325007-696FC083-825A-4860-B017-94DEE859E700Q37541868-BDBC2851-CE97-4128-A520-7EBA1BF83F99Q37708798-461F7A1D-40C4-411C-B38D-4E23A983CEA8Q38681814-B8DB1139-5E77-4DA1-B323-2654286E9CD4Q38686915-1667FF52-B058-4F02-93BA-F8F52225BC8FQ38943973-C97D7E1B-1EA2-40D9-AF3D-983152DAD1A8Q38979403-3BD0BBB0-097C-4803-952C-FE01E9BCD7D0Q39177792-2DF72CD2-5E4A-4E9E-A6D5-0E18A291F453Q40002181-B0C94EAC-F13C-42EF-8274-60AA2BC4BD9EQ41663752-C700317C-1776-4094-9121-96D456263A43Q42261210-2E27238D-2DB2-48AF-95B3-08353EE73BA8Q47548602-2E2B62DF-B618-4085-9C28-781EE408C449Q50057730-26A4B244-5BC2-440D-AF9D-50DFDBD50065Q50942246-DD0E92AC-76DD-4DEB-9261-BD97B97F2158Q55313598-1575DC87-58B7-4B9A-BE45-BA6FFEE595B7
P2860
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Targeted sequencing using a 47 ...... P) in -17p high risk disease.
@en
type
label
Targeted sequencing using a 47 ...... P) in -17p high risk disease.
@en
prefLabel
Targeted sequencing using a 47 ...... P) in -17p high risk disease.
@en
P2093
P2860
P50
P356
P1476
Targeted sequencing using a 47 ...... ) P) in -17p high risk disease
@en
P2093
A Keith Stewart
Chang Xin Shi
Christian Langer
Esteban Braggio
Gregory Ahmann
Jan B Egan
Jessica Schmidt
Jorge Monge
Lars Bullinger
P2860
P304
P356
10.1111/BJH.13171
P407
P577
2014-10-10T00:00:00Z